Celyad Oncology (LTS:0QFK) 3-Month Share Buyback Ratio: 0.00% (As of Dec. 2025 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0QFK Celyad Oncology SA LTS:0QFK
23 GF Score
Price €0.27
GF Value €0.67
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Celyad Oncology 3-Month Share Buyback Ratio?

Celyad Oncology LTS:0QFK 23 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus rates LTS:0QFK with a GF Score™ of 23/100 and a GF Value™ of €0.67 (Possible Value Trap). The stock has 6 warning signs investors should review.

3-Month Share Buyback Ratio only apply to companies whose reporting frequency is 3 months.

LTS:0QFK
23GF Score
Celyad Oncology SA LTS:0QFK
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a 3-Month Share Buyback Ratio of 0.00 mean?
Celyad Oncology (LTS:0QFK) has a 3-Month Share Buyback Ratio of 0.00 as of Dec. 2025. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Celyad Oncology and its competitors.
Is Celyad Oncology's 3-Month Share Buyback Ratio too high?
Celyad Oncology's current 3-Month Share Buyback Ratio is 0.00. Overall, Celyad Oncology has a GF Score™ of 23/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Celyad Oncology's 3-Month Share Buyback Ratio compare to VRTX and REGN?
Celyad Oncology's 3-Month Share Buyback Ratio of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Biotechnology company?
A good 3-Month Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Celyad Oncology and its competitors. Celyad Oncology's current 3-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celyad Oncology stock overvalued right now?
Based on GuruFocus' analysis, Celyad Oncology (LTS:0QFK) is currently considered Possible Value Trap. The stock's GF Value™ is €0.67, compared to a current price of €0.27 — trading 60.3% below its estimated fair value. The current 3-Month Share Buyback Ratio is 0.00. Celyad Oncology's overall GF Score™ is 23/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Celyad Oncology (LTS:0QFK), the current 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celyad Oncology (LTS:0QFK) Overvalued in 2026?

Based on GuruFocus' analysis, Celyad Oncology stock appears to be undervalued. The current stock price of €0.27 is trading 60.3% below its estimated GF Value™ of €0.67. GuruFocus considers Celyad Oncology to be Possible Value Trap.

Key valuation signals for LTS:0QFK:

  • 3-Month Share Buyback Ratio: 0.00
  • GF Value™: €0.67 vs. price of €0.27 (60.3% below fair value)
  • GF Score™: 23/100 with 6 warning signs

No single metric tells the full story. See the LTS:0QFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celyad Oncology Business Description

Address Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
23GF Score

Get the complete analysis for LTS:0QFK

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.27
Price
€0.67
GF Value